Par Drugs And Chemicals Limited has informed the Exchange about Copy of Newspaper Publication
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Par Drugs and Chemicals Limited reported Q4 FY26 standalone total income of Rs. 1,961.08 lakh, significantly down from Rs. 2,933.95 lakh in Q3 and Rs. 2,232.99 lakh in Q4 FY25. Net profit after tax dropped sharply to Rs. 85.36 lakh from Rs. 479.72 lakh in Q3. For the full year FY26, total income increased marginally to Rs. 10,365.56 lakh from Rs. 10,097.35 lakh in FY25. However, full year net profit after tax declined to Rs. 1,310.86 lakh from Rs. 1,335.79 lakh, with EPS at Rs. 10.65 versus Rs. 10.86 in the prior year. The company is primarily engaged in manufacturing Active Pharmaceutical Ingredients (API) as a single business segment and has no subsidiaries, associates, or joint ventures.
The Q4 results show significant deterioration with sharp declines in both revenue and profitability compared to the preceding quarter. Full year performance remained relatively stable with marginal revenue growth but slight profit decline. The weak Q4 showing may create negative sentiment for the stock.